Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positron Corporation

This article was originally published in The Gray Sheet

Executive Summary

Private placement of 42.2 mil. shares of common stock raises $12.7 mil. About 21.5 mil. five-year warrants also were issued in connection with the financing. Proceeds will be used for manufacturing and marketing of the firm's Posicam postitron emission tomography scanners, as well as debt repayment and general corporate purposes. The funding follows Imatron's January purchase of a controlling interest in Positron and is in line with Imatron's plans to reactivate and recapitalize the dormant PET maker (1"The Gray Sheet" Feb. 1, p. 15). The capital infusion comes on the heels of recent favorable reimbursement recommendations for a broad range of PET procedures from the Health Care Financing Administration (2"The Gray Sheet" March 15, p. 20)

You may also be interested in...



HCFA Expanding PET Medicare Coverage To Three More Cancer Indications

Medicare will cover three additional indications for positron emission tomography (PET) in the diagnosis and management of cancer, the Health Care Financing Administration announced March 8.

Imatron Aims To Reactivate And Recapitalize Dormant PET Maker

Imatron is looking to revitalize positron emission tomography scanner maker Positron Corporation following the firm's Jan. 25 purchase of 51%, or 9 mil. shares of Positron common stock.

Making The Case For A Legislative Deal On Drug Pricing

Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing behind us with a legislative compromise.

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel